Herbalife stock has delivered a steep decline of around 75% over the past five years, yet on current checks it screens as undervalued, which sets up a clear question over whether recent share price strength is finally bringing it closer to a more reasonable level or leaving some upside on the table.

• Over the past five years, Herbalife shareholders have seen the share price fall about 75%, which means even the recent rebound sits against a long period of value erosion.
• The new Herbalife and IIT Madras Centre of Excellence on Plant Cell Fermentation Technology can support sentiment around future product development and margins, while any execution or commercialisation setbacks around these initiatives may weigh on how much value investors are willing to ascribe to the stock.
• Herbalife currently passes 5 of 6 valuation checks, so the broader assessment leans toward the stock looking cheap on traditional metrics, as reflected in its value score of 5.

The stock's next move may depend on whether that combination of long term share price damage and stronger recent performance already reflects the valuation upside that these checks are pointing to.

Is Herbalife a Bargain on Earnings?

The P/E ratio is a useful way to see what the market is paying for each dollar of Herbalife earnings today. Herbalife trades on a P/E of about 5.7x, compared with roughly 18.5x for the wider Personal Products industry and around 14.6x for its peer group, so the stock is priced at a clear discount to both benchmarks.

On Simply Wall St’s tailored fair multiple of about 14.3x, which reflects Herbalife sector, risk profile and financial characteristics, the current 5.7x implies the shares trade on a materially lower earnings multiple than that model indicates. Despite the recent attention around Herbalife work with IIT Madras on plant cell fermentation technology, the market is still pricing Herbalife earnings at a sizeable markdown to peers and to this fair-value yardstick.

Overall, Herbalife appears undervalued on its current P/E multiple when set against both industry norms and the modelled fair ratio.

The Herbalife Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Herbalife's valuation puzzle leaves off by explaining which combinations of future growth, margins and earnings would need to occur for the stock to be worth materially more or less than it is today on the market. Each Narrative presents Herbalife's fair value as a thesis about the business that can be revisited over time, rather than a one off snapshot, and they are available on the Community page.

Community views on Herbalife sit far apart, with one camp focused on execution upside and the other on structural headwinds.

Bull case: 28% undervalued

"Herbalife's transformation into a next-generation, data-driven wellness company, including its investments in product innovation (e.g., healthy lifespan supplements, MultiBurn) and personalized technology platforms (Pro2col, Link Biosciences), positions it to capitalize on the major secular trend of rising consumer demand for personalized and preventative health solutions, potentially leading to increased revenue and higher customer retention..."

Bear case: 46% overvalued

"Mounting debt obligations and high leverage constrain Herbalife's financial flexibility to invest in innovation or weather industry shocks, while legal and reputational risks from ongoing scrutiny and litigation may force further margin concessions or impede international expansion, putting long-term earnings power and shareholder value at significant risk..."

Do you think there's more to the story for Herbalife? Head over to our Community to see what others are saying!

The Bottom Line

Herbalife screens as undervalued on its current market multiples, which suggests the current price builds in a fair amount of caution about its prospects. The crux for you as an investor is whether that discount reflects an opportunity for a re rating if execution improves, or whether it is the market correctly pricing in balance sheet, legal and business model risks highlighted by the bear case. From here, the key swing factor is whether Herbalife can translate its product and technology initiatives into durable earnings quality that convinces the market to close at least part of that valuation gap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.